-
3
-
-
67650944993
-
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
-
Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009; 460:392-395.
-
(2009)
Nature
, vol.460
, pp. 392-395
-
-
Harrison, D.E.1
Strong, R.2
Sharp, Z.D.3
Nelson, J.F.4
Astle, C.M.5
Flurkey, K.6
Nadon, N.L.7
Wilkinson, J.E.8
Frenkel, K.9
Carter, C.S.10
Pahor, M.11
Javors, M.A.12
Fernandez, E.13
-
4
-
-
72649091698
-
Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster
-
Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, Foley A and Partridge L. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell metabolism. 2010; 11:35-46.
-
(2010)
Cell metabolism
, vol.11
, pp. 35-46
-
-
Bjedov, I.1
Toivonen, J.M.2
Kerr, F.3
Slack, C.4
Jacobson, J.5
Foley, A.6
Partridge, L.7
-
5
-
-
84860461929
-
TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO
-
Robida-Stubbs S, Glover-Cutter K, Lamming DW, Mizunuma M, Narasimhan SD, Neumann-Haefelin E, Sabatini DM and Blackwell TK. TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. Cell metabolism. 2012; 15:713-724.
-
(2012)
Cell metabolism
, vol.15
, pp. 713-724
-
-
Robida-Stubbs, S.1
Glover-Cutter, K.2
Lamming, D.W.3
Mizunuma, M.4
Narasimhan, S.D.5
Neumann-Haefelin, E.6
Sabatini, D.M.7
Blackwell, T.K.8
-
6
-
-
30944458446
-
Extension of chronological life span in yeast by decreased TOR pathway signaling
-
Powers RW, 3rd, Kaeberlein M, Caldwell SD, Kennedy BK and Fields S. Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes & development. 2006; 20:174-184.
-
(2006)
Genes & development
, vol.20
, pp. 174-184
-
-
Powers III, R.W.1
Kaeberlein, M.2
Caldwell, S.D.3
Kennedy, B.K.4
Fields, S.5
-
7
-
-
84863393597
-
Exerciseinduced BCL2-regulated autophagy is required for muscle glucose homeostasis
-
He C, Bassik MC, Moresi V, Sun K, Wei Y, Zou Z, An Z, Loh J, Fisher J, Sun Q, Korsmeyer S, Packer M, May HI, et al. Exerciseinduced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature. 2012; 481:511-515.
-
(2012)
Nature
, vol.481
, pp. 511-515
-
-
He, C.1
Bassik, M.C.2
Moresi, V.3
Sun, K.4
Wei, Y.5
Zou, Z.6
An, Z.7
Loh, J.8
Fisher, J.9
Sun, Q.10
Korsmeyer, S.11
Packer, M.12
May, H.I.13
-
8
-
-
84861085191
-
Autophagy mediates the metabolic benefits of endurance training
-
Galluzzi L and Kroemer G. Autophagy mediates the metabolic benefits of endurance training. Circulation research. 2012; 110:1276-1278.
-
(2012)
Circulation research
, vol.110
, pp. 1276-1278
-
-
Galluzzi, L.1
Kroemer, G.2
-
9
-
-
77953624320
-
Linking calorie restriction to longevity through sirtuins and autophagy: any role for TOR
-
Blagosklonny MV. Linking calorie restriction to longevity through sirtuins and autophagy: any role for TOR. Cell death & disease. 2010; 1:e12.
-
(2010)
Cell death & disease
, vol.1
-
-
Blagosklonny, M.V.1
-
10
-
-
84874192375
-
FOXO3A directs a protective autophagy program in haematopoietic stem cells
-
Warr MR, Binnewies M, Flach J, Reynaud D, Garg T, Malhotra R, Debnath J and Passegue E. FOXO3A directs a protective autophagy program in haematopoietic stem cells. Nature. 2013; 494:323-327.
-
(2013)
Nature
, vol.494
, pp. 323-327
-
-
Warr, M.R.1
Binnewies, M.2
Flach, J.3
Reynaud, D.4
Garg, T.5
Malhotra, R.6
Debnath, J.7
Passegue, E.8
-
11
-
-
70449529855
-
Induction of autophagy by spermidine promotes longevity
-
Eisenberg T, Knauer H, Schauer A, Buttner S, Ruckenstuhl C, Carmona-Gutierrez D, Ring J, Schroeder S, Magnes C, Antonacci L, Fussi H, Deszcz L, Hartl R, et al. Induction of autophagy by spermidine promotes longevity. Nature cell biology. 2009; 11:1305-1314.
-
(2009)
Nature cell biology
, vol.11
, pp. 1305-1314
-
-
Eisenberg, T.1
Knauer, H.2
Schauer, A.3
Buttner, S.4
Ruckenstuhl, C.5
Carmona-Gutierrez, D.6
Ring, J.7
Schroeder, S.8
Magnes, C.9
Antonacci, L.10
Fussi, H.11
Deszcz, L.12
Hartl, R.13
-
12
-
-
79953043473
-
Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy
-
Morselli E, Maiuri MC, Markaki M, Megalou E, Pasparaki A, Palikaras K, Criollo A, Galluzzi L, Malik SA, Vitale I, Michaud M, Madeo F, Tavernarakis N, et al. Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. Cell death & disease. 2010; 1:e10.
-
(2010)
Cell death & disease
, vol.1
-
-
Morselli, E.1
Maiuri, M.C.2
Markaki, M.3
Megalou, E.4
Pasparaki, A.5
Palikaras, K.6
Criollo, A.7
Galluzzi, L.8
Malik, S.A.9
Vitale, I.10
Michaud, M.11
Madeo, F.12
Tavernarakis, N.13
-
13
-
-
77950656808
-
Autophagy mediates pharmacological lifespan extension by spermidine and resveratrol
-
Morselli E, Galluzzi L, Kepp O, Criollo A, Maiuri MC, Tavernarakis N, Madeo F and Kroemer G. Autophagy mediates pharmacological lifespan extension by spermidine and resveratrol. Aging. 2009; 1:961-970.
-
(2009)
Aging
, vol.1
, pp. 961-970
-
-
Morselli, E.1
Galluzzi, L.2
Kepp, O.3
Criollo, A.4
Maiuri, M.C.5
Tavernarakis, N.6
Madeo, F.7
Kroemer, G.8
-
17
-
-
35448981935
-
Autophagy: from phenomenology to molecular understanding in less than a decade
-
Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nature reviews Molecular cell biology. 2007; 8:931-937.
-
(2007)
Nature reviews Molecular cell biology
, vol.8
, pp. 931-937
-
-
Klionsky, D.J.1
-
18
-
-
35848937781
-
Autophagy is required for dietary restriction-mediated life span extension in C. elegans
-
Jia K and Levine B. Autophagy is required for dietary restriction-mediated life span extension in C. elegans. Autophagy. 2007; 3:597-599.
-
(2007)
Autophagy
, vol.3
, pp. 597-599
-
-
Jia, K.1
Levine, B.2
-
19
-
-
40149105890
-
A role for autophagy in the extension of lifespan by dietary restriction in C. elegans
-
Hansen M, Chandra A, Mitic LL, Onken B, Driscoll M and Kenyon C. A role for autophagy in the extension of lifespan by dietary restriction in C. elegans. PLoS genetics. 2008; 4:e24.
-
(2008)
PLoS genetics
, vol.4
-
-
Hansen, M.1
Chandra, A.2
Mitic, L.L.3
Onken, B.4
Driscoll, M.5
Kenyon, C.6
-
20
-
-
67650243271
-
Autophagy genes mediate the effect of calcineurin on life span in C. elegans
-
Dwivedi M, Song HO and Ahnn J. Autophagy genes mediate the effect of calcineurin on life span in C. elegans. Autophagy. 2009; 5:604-607.
-
(2009)
Autophagy
, vol.5
, pp. 604-607
-
-
Dwivedi, M.1
Song, H.O.2
Ahnn, J.3
-
21
-
-
84878917282
-
Autophagy mediates caloric restriction-induced lifespan extension in Arabidopsis
-
Minina EA, Sanchez-Vera V, Moschou PN, Suarez MF, Sundberg E, Weih M and Bozhkov PV. Autophagy mediates caloric restriction-induced lifespan extension in Arabidopsis. Aging cell. 2013; 12:327-329.
-
(2013)
Aging cell
, vol.12
, pp. 327-329
-
-
Minina, E.A.1
Sanchez-Vera, V.2
Moschou, P.N.3
Suarez, M.F.4
Sundberg, E.5
Weih, M.6
Bozhkov, P.V.7
-
22
-
-
84883114523
-
Overexpression of Atg5 in mice activates autophagy and extends lifespan
-
Pyo JO, Yoo SM, Ahn HH, Nah J, Hong SH, Kam TI, Jung S and Jung YK. Overexpression of Atg5 in mice activates autophagy and extends lifespan. Nature communications. 2013; 4:2300.
-
(2013)
Nature communications
, vol.4
, pp. 2300
-
-
Pyo, J.O.1
Yoo, S.M.2
Ahn, H.H.3
Nah, J.4
Hong, S.H.5
Kam, T.I.6
Jung, S.7
Jung, Y.K.8
-
23
-
-
33947401070
-
Autophagy regulates ageing in C. elegans
-
Hars ES, Qi H, Ryazanov AG, Jin S, Cai L, Hu C and Liu LF. Autophagy regulates ageing in C. elegans. Autophagy. 2007; 3:93-95.
-
(2007)
Autophagy
, vol.3
, pp. 93-95
-
-
Hars, E.S.1
Qi, H.2
Ryazanov, A.G.3
Jin, S.4
Cai, L.5
Hu, C.6
Liu, L.F.7
-
24
-
-
79959354999
-
Mitochondria and the autophagy-inflammation-cell death axis in organismal aging
-
Green DR, Galluzzi L and Kroemer G. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science. 2011; 333:1109-1112.
-
(2011)
Science
, vol.333
, pp. 1109-1112
-
-
Green, D.R.1
Galluzzi, L.2
Kroemer, G.3
-
25
-
-
69349087479
-
Anti-and pro-tumor functions of autophagy
-
Morselli E, Galluzzi L, Kepp O, Vicencio JM, Criollo A, Maiuri MC and Kroemer G. Anti-and pro-tumor functions of autophagy. Biochimica et biophysica acta. 2009; 1793(9):1524-1532.
-
(2009)
Biochimica et biophysica acta
, vol.1793
, Issue.9
, pp. 1524-1532
-
-
Morselli, E.1
Galluzzi, L.2
Kepp, O.3
Vicencio, J.M.4
Criollo, A.5
Maiuri, M.C.6
Kroemer, G.7
-
26
-
-
84861526009
-
Deconvoluting the context-dependent role for autophagy in cancer
-
White E. Deconvoluting the context-dependent role for autophagy in cancer. Nature reviews Cancer. 2012; 12:401-410.
-
(2012)
Nature reviews Cancer
, vol.12
, pp. 401-410
-
-
White, E.1
-
27
-
-
78649338141
-
Autophagy and the integrated stress response
-
Kroemer G, Marino G and Levine B. Autophagy and the integrated stress response. Molecular cell. 2010; 40:280-293.
-
(2010)
Molecular cell
, vol.40
, pp. 280-293
-
-
Kroemer, G.1
Marino, G.2
Levine, B.3
-
28
-
-
83755219008
-
Hormesis, cell death and aging
-
Martins I, Galluzzi L and Kroemer G. Hormesis, cell death and aging. Aging. 2011; 3:821-828.
-
(2011)
Aging
, vol.3
, pp. 821-828
-
-
Martins, I.1
Galluzzi, L.2
Kroemer, G.3
-
29
-
-
78751672975
-
Autophagy in immunity and inflammation
-
Levine B, Mizushima N and Virgin HW. Autophagy in immunity and inflammation. Nature. 2011; 469:323-335.
-
(2011)
Nature
, vol.469
, pp. 323-335
-
-
Levine, B.1
Mizushima, N.2
Virgin, H.W.3
-
30
-
-
84879107779
-
Intestinal epithelial autophagy is essential for host defense against invasive bacteria
-
Benjamin JL, Sumpter R, Jr., Levine B and Hooper LV. Intestinal epithelial autophagy is essential for host defense against invasive bacteria. Cell host & microbe. 2013; 13:723-734.
-
(2013)
Cell host & microbe
, vol.13
, pp. 723-734
-
-
Benjamin, J.L.1
Sumpter Jr, R.2
Levine, B.3
Hooper, L.V.4
-
31
-
-
84878253490
-
Autophagy-assisted antigen crosspresentation: Autophagosome as the argo of shared tumorspecific antigens and DAMPs
-
Yi Y, Zhou Z, Shu S, Fang Y, Twitty C, Hilton TL, Aung S, Urba WJ, Fox BA, Hu HM and Li Y. Autophagy-assisted antigen crosspresentation: Autophagosome as the argo of shared tumorspecific antigens and DAMPs. Oncoimmunology. 2012; 1:976-978.
-
(2012)
Oncoimmunology
, vol.1
, pp. 976-978
-
-
Yi, Y.1
Zhou, Z.2
Shu, S.3
Fang, Y.4
Twitty, C.5
Hilton, T.L.6
Aung, S.7
Urba, W.J.8
Fox, B.A.9
Hu, H.M.10
Li, Y.11
-
33
-
-
84871349185
-
Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39
-
Michaud M, Sukkurwala AQ, Martins I, Shen S, Zitvogel L and Kroemer G. Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39. Oncoimmunology. 2012; 1:393-395.
-
(2012)
Oncoimmunology
, vol.1
, pp. 393-395
-
-
Michaud, M.1
Sukkurwala, A.Q.2
Martins, I.3
Shen, S.4
Zitvogel, L.5
Kroemer, G.6
-
35
-
-
84886943831
-
A perspective on new immune adjuvant principles: Reprogramming inflammatory states to permit clearance of cancer cells and other age-associated cellular pathologies
-
Prendergast GC and Metz R. A perspective on new immune adjuvant principles: Reprogramming inflammatory states to permit clearance of cancer cells and other age-associated cellular pathologies. Oncoimmunology. 2012; 1:924-929.
-
(2012)
Oncoimmunology
, vol.1
, pp. 924-929
-
-
Prendergast, G.C.1
Metz, R.2
-
36
-
-
24644445998
-
Rapamycin: an anti-cancer immunosuppressant?
-
Law BK. Rapamycin: an anti-cancer immunosuppressant? Critical reviews in oncology/hematology. 2005; 56:47-60.
-
(2005)
Critical reviews in oncology/hematology
, vol.56
, pp. 47-60
-
-
Law, B.K.1
-
37
-
-
0035166843
-
Sirolimus: a new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation
-
Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association -European Renal Association
-
Morelon E, Mamzer-Bruneel MF, Peraldi MN and Kreis H. Sirolimus: a new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association -European Renal Association. 2001; 16:18-20.
-
(2001)
, vol.16
, pp. 18-20
-
-
Morelon, E.1
Mamzer-Bruneel, M.F.2
Peraldi, M.N.3
Kreis, H.4
-
39
-
-
0032573044
-
Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation
-
Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU and Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation. 1998; 66:1040-1046.
-
(1998)
Transplantation
, vol.66
, pp. 1040-1046
-
-
Kahan, B.D.1
Podbielski, J.2
Napoli, K.L.3
Katz, S.M.4
Meier-Kriesche, H.U.5
Van Buren, C.T.6
-
40
-
-
0344074657
-
Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients
-
Brattstrom C, Sawe J, Tyden G, Herlenius G, Claesson K, Zimmerman J and Groth CG. Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. Therapeutic drug monitoring. 1997; 19:397-406.
-
(1997)
Therapeutic drug monitoring
, vol.19
, pp. 397-406
-
-
Brattstrom, C.1
Sawe, J.2
Tyden, G.3
Herlenius, G.4
Claesson, K.5
Zimmerman, J.6
Groth, C.G.7
-
41
-
-
84898003300
-
-
Immunosuppressants in cancer prevention and therapy Oncoimmunology
-
Blagosklonny MV. Immunosuppressants in cancer prevention and therapy Oncoimmunology. 2013; 2:e26961.
-
(2013)
, vol.2
-
-
Blagosklonny, M.V.1
-
42
-
-
4043142865
-
Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies
-
Mathew T, Kreis H and Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clinical transplantation. 2004; 18:446-449.
-
(2004)
Clinical transplantation
, vol.18
, pp. 446-449
-
-
Mathew, T.1
Kreis, H.2
Friend, P.3
-
43
-
-
33645067673
-
Individualization of immunosuppressive therapy III. Sirolimus associated with a reduced incidence of malignancy
-
Yakupoglu YK, Buell JF, Woodle S and Kahan BD. Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy. Transplantation proceedings. 2006; 38:358-361.
-
(2006)
Transplantation proceedings
, vol.38
, pp. 358-361
-
-
Yakupoglu, Y.K.1
Buell, J.F.2
Woodle, S.3
Kahan, B.D.4
-
44
-
-
33645458234
-
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation
-
Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Claesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. Journal of the American Society of Nephrology: JASN. 2006; 17:581-589.
-
(2006)
Journal of the American Society of Nephrology: JASN
, vol.17
, pp. 581-589
-
-
Campistol, J.M.1
Eris, J.2
Oberbauer, R.3
Friend, P.4
Hutchison, B.5
Morales, J.M.6
Claesson, K.7
Stallone, G.8
Russ, G.9
Rostaing, L.10
Kreis, H.11
Burke, J.T.12
Brault, Y.13
-
45
-
-
80053294998
-
Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial
-
Alberu J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M, Neylan JF, Korth-Bradley J, Goldberg-Alberts R, Maller ES and Sirolimus CTSG. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation. 2011; 92:303-310.
-
(2011)
Transplantation
, vol.92
, pp. 303-310
-
-
Alberu, J.1
Pascoe, M.D.2
Campistol, J.M.3
Schena, F.P.4
Rial Mdel, C.5
Polinsky, M.6
Neylan, J.F.7
Korth-Bradley, J.8
Goldberg-Alberts, R.9
Maller, E.S.10
Sirolimus, C.T.S.G.11
-
46
-
-
27644436740
-
Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies
-
Kauffman HM, Cherikh WS, Cheng Y, Hanto DW and Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005; 80:883-889.
-
(2005)
Transplantation
, vol.80
, pp. 883-889
-
-
Kauffman, H.M.1
Cherikh, W.S.2
Cheng, Y.3
Hanto, D.W.4
Kahan, B.D.5
-
47
-
-
77952940222
-
Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial
-
Salgo R, Gossmann J, Schofer H, Kachel HG, Kuck J, Geiger H, Kaufmann R and Scheuermann EH. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2010; 10:1385-1393.
-
(2010)
American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
, vol.10
, pp. 1385-1393
-
-
Salgo, R.1
Gossmann, J.2
Schofer, H.3
Kachel, H.G.4
Kuck, J.5
Geiger, H.6
Kaufmann, R.7
Scheuermann, E.H.8
-
48
-
-
84860471709
-
Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer
-
Campbell SB, Walker R, Tai SS, Jiang Q and Russ GR. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2012; 12:1146-1156.
-
(2012)
American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
, vol.12
, pp. 1146-1156
-
-
Campbell, S.B.1
Walker, R.2
Tai, S.S.3
Jiang, Q.4
Russ, G.R.5
-
49
-
-
0029128391
-
Risk of neoplasia in renal transplant patients
-
London NJ, Farmery SM, Will EJ, Davison AM and Lodge JP. Risk of neoplasia in renal transplant patients. Lancet. 1995; 346:403-406.
-
(1995)
Lancet
, vol.346
, pp. 403-406
-
-
London, N.J.1
Farmery, S.M.2
Will, E.J.3
Davison, A.M.4
Lodge, J.P.5
-
50
-
-
33645454799
-
Complete regression of visceral Kaposi's sarcoma after conversion to sirolimus
-
Mohsin N, Budruddin M, Pakkyara A, Darweesh A, Nayyer M, Amitabh J and Daar AS. Complete regression of visceral Kaposi's sarcoma after conversion to sirolimus. Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation. 2005; 3:366-369.
-
(2005)
Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation
, vol.3
, pp. 366-369
-
-
Mohsin, N.1
Budruddin, M.2
Pakkyara, A.3
Darweesh, A.4
Nayyer, M.5
Amitabh, J.6
Daar, A.S.7
-
51
-
-
32944461120
-
Kaposi's sarcoma in renal transplant recipients
-
Zmonarski SC, Boratynska M, Puziewicz-Zmonarska A, Kazimierczak K and Klinger M. Kaposi's sarcoma in renal transplant recipients. Annals of transplantation: quarterly of the Polish Transplantation Society. 2005; 10:59-65.
-
(2005)
Annals of transplantation: quarterly of the Polish Transplantation Society
, vol.10
, pp. 59-65
-
-
Zmonarski, S.C.1
Boratynska, M.2
Puziewicz-Zmonarska, A.3
Kazimierczak, K.4
Klinger, M.5
-
52
-
-
17844381895
-
Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment
-
Zmonarski SC, Boratynska M, Rabczynski J, Kazimierczak K and Klinger M. Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment. Transplantation proceedings. 2005; 37:964-966.
-
(2005)
Transplantation proceedings
, vol.37
, pp. 964-966
-
-
Zmonarski, S.C.1
Boratynska, M.2
Rabczynski, J.3
Kazimierczak, K.4
Klinger, M.5
-
53
-
-
33646052253
-
Sirolimus-induced remission of posttransplantation lymphoproliferative disorder
-
Cullis B, D'Souza R, McCullagh P, Harries S, Nicholls A, Lee R and Bingham C. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2006; 47:e67-72.
-
(2006)
American journal of kidney diseases: the official journal of the National Kidney Foundation
, vol.47
-
-
Cullis, B.1
D'Souza, R.2
McCullagh, P.3
Harries, S.4
Nicholls, A.5
Lee, R.6
Bingham, C.7
-
54
-
-
20144367584
-
Sirolimus for Kaposi's sarcoma in renal-transplant recipients
-
Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP and Grandaliano G. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. The New England journal of medicine. 2005; 352:1317-1323.
-
(2005)
The New England journal of medicine
, vol.352
, pp. 1317-1323
-
-
Stallone, G.1
Schena, A.2
Infante, B.3
Di Paolo, S.4
Loverre, A.5
Maggio, G.6
Ranieri, E.7
Gesualdo, L.8
Schena, F.P.9
Grandaliano, G.10
-
55
-
-
2942562298
-
Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy
-
Dittrich E, Schmaldienst S, Soleiman A, Horl WH and Pohanka E. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transplant international: official journal of the European Society for Organ Transplantation. 2004; 17:215-220.
-
(2004)
Transplant international: official journal of the European Society for Organ Transplantation
, vol.17
, pp. 215-220
-
-
Dittrich, E.1
Schmaldienst, S.2
Soleiman, A.3
Horl, W.H.4
Pohanka, E.5
-
56
-
-
28544432476
-
Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state
-
Thaunat O, Beaumont C, Chatenoud L, Lechaton S, Mamzer-Bruneel MF, Varet B, Kreis H and Morelon E. Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation. 2005; 80:1212-1219.
-
(2005)
Transplantation
, vol.80
, pp. 1212-1219
-
-
Thaunat, O.1
Beaumont, C.2
Chatenoud, L.3
Lechaton, S.4
Mamzer-Bruneel, M.F.5
Varet, B.6
Kreis, H.7
Morelon, E.8
-
57
-
-
48649107474
-
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
-
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372:449-456.
-
(2008)
Lancet
, vol.372
, pp. 449-456
-
-
Motzer, R.J.1
Escudier, B.2
Oudard, S.3
Hutson, T.E.4
Porta, C.5
Bracarda, S.6
Grunwald, V.7
Thompson, J.A.8
Figlin, R.A.9
Hollaender, N.10
Urbanowitz, G.11
Berg, W.J.12
Kay, A.13
-
58
-
-
78049510428
-
Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis
-
Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T and Franz DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. The New England journal of medicine. 2010; 363:1801-1811.
-
(2010)
The New England journal of medicine
, vol.363
, pp. 1801-1811
-
-
Krueger, D.A.1
Care, M.M.2
Holland, K.3
Agricola, K.4
Tudor, C.5
Mangeshkar, P.6
Wilson, K.A.7
Byars, A.8
Sahmoud, T.9
Franz, D.N.10
-
59
-
-
79851500081
-
Everolimus for advanced pancreatic neuroendocrine tumors
-
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, et al. Everolimus for advanced pancreatic neuroendocrine tumors. The New England journal of medicine. 2011; 364:514-523.
-
(2011)
The New England journal of medicine
, vol.364
, pp. 514-523
-
-
Yao, J.C.1
Shah, M.H.2
Ito, T.3
Bohas, C.L.4
Wolin, E.M.5
Van Cutsem, E.6
Hobday, T.J.7
Okusaka, T.8
Capdevila, J.9
de Vries, E.G.10
Tomassetti, P.11
Pavel, M.E.12
Hoosen, S.13
-
60
-
-
84863078767
-
Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer
-
Baselga J, Campone M, Piccart M, Burris HA, 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, et al. Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer. The New England journal of medicine. 2012; 366:520-529.
-
(2012)
The New England journal of medicine
, vol.366
, pp. 520-529
-
-
Baselga, J.1
Campone, M.2
Piccart, M.3
Burris III, H.A.4
Rugo, H.S.5
Sahmoud, T.6
Noguchi, S.7
Gnant, M.8
Pritchard, K.I.9
Lebrun, F.10
Beck, J.T.11
Ito, Y.12
Yardley, D.13
-
62
-
-
37349084974
-
A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus
-
Hill JA, Hummel M, Starling RC, Kobashigawa JA, Perrone SV, Arizon JM, Simonsen S, Abeywickrama KH and Bara C. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation. 2007; 84:1436-1442.
-
(2007)
Transplantation
, vol.84
, pp. 1436-1442
-
-
Hill, J.A.1
Hummel, M.2
Starling, R.C.3
Kobashigawa, J.A.4
Perrone, S.V.5
Arizon, J.M.6
Simonsen, S.7
Abeywickrama, K.H.8
Bara, C.9
-
63
-
-
45449112352
-
Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials
-
Demopoulos L, Polinsky M, Steele G, Mines D, Blum M, Caulfield M, Adamkovic A, Liu Q, Harler MB, Hahn C and Singh A. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplantation proceedings. 2008; 40:1407-1410.
-
(2008)
Transplantation proceedings
, vol.40
, pp. 1407-1410
-
-
Demopoulos, L.1
Polinsky, M.2
Steele, G.3
Mines, D.4
Blum, M.5
Caulfield, M.6
Adamkovic, A.7
Liu, Q.8
Harler, M.B.9
Hahn, C.10
Singh, A.11
-
64
-
-
84886944522
-
EGFR inhibitors MHC expression and immune responses: Can EGFR inhibitors be used as immune response modifiers?
-
Pollack BP. EGFR inhibitors, MHC expression and immune responses: Can EGFR inhibitors be used as immune response modifiers? Oncoimmunology. 2012; 1:71-74.
-
(2012)
Oncoimmunology
, vol.1
, pp. 71-74
-
-
Pollack, B.P.1
-
66
-
-
54549089738
-
Hypoxia signalling through mTOR and the unfolded protein response in cancer
-
Wouters BG and Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nature reviews Cancer. 2008; 8:851-864.
-
(2008)
Nature reviews Cancer
, vol.8
, pp. 851-864
-
-
Wouters, B.G.1
Koritzinsky, M.2
-
67
-
-
67749111502
-
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
-
Shackelford DB and Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nature reviews Cancer. 2009; 9:563-575.
-
(2009)
Nature reviews Cancer
, vol.9
, pp. 563-575
-
-
Shackelford, D.B.1
Shaw, R.J.2
-
68
-
-
0141640858
-
Negative regulation of interleukin-12 production by a rapamycin-sensitive signaling pathway: a brief communication
-
Uthaisangsook S, Day NK, Hitchcock R, Lerner A, James-Yarish M, Good RA and Haraguchi S. Negative regulation of interleukin-12 production by a rapamycin-sensitive signaling pathway: a brief communication. Experimental biology and medicine. 2003; 228:1023-1027.
-
(2003)
Experimental biology and medicine
, vol.228
, pp. 1023-1027
-
-
Uthaisangsook, S.1
Day, N.K.2
Hitchcock, R.3
Lerner, A.4
James-Yarish, M.5
Good, R.A.6
Haraguchi, S.7
-
69
-
-
33745013651
-
Intracellular network of phosphatidylinositol 3-kinase, mammalian target of the rapamycin/70 kDa ribosomal S6 kinase 1, and mitogen-activated protein kinases pathways for regulating mycobacteria-induced IL-23 expression in human macrophages
-
Yang CS, Song CH, Lee JS, Jung SB, Oh JH, Park J, Kim HJ, Park JK, Paik TH and Jo EK. Intracellular network of phosphatidylinositol 3-kinase, mammalian target of the rapamycin/70 kDa ribosomal S6 kinase 1, and mitogen-activated protein kinases pathways for regulating mycobacteria-induced IL-23 expression in human macrophages. Cellular microbiology. 2006; 8:1158-1171.
-
(2006)
Cellular microbiology
, vol.8
, pp. 1158-1171
-
-
Yang, C.S.1
Song, C.H.2
Lee, J.S.3
Jung, S.B.4
Oh, J.H.5
Park, J.6
Kim, H.J.7
Park, J.K.8
Paik, T.H.9
Jo, E.K.10
-
70
-
-
77956893188
-
Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses
-
Ferrer IR, Wagener ME, Robertson JM, Turner AP, Araki K, Ahmed R, Kirk AD, Larsen CP and Ford ML. Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. Journal of immunology. 2010; 185:2004-2008.
-
(2010)
Journal of immunology
, vol.185
, pp. 2004-2008
-
-
Ferrer, I.R.1
Wagener, M.E.2
Robertson, J.M.3
Turner, A.P.4
Araki, K.5
Ahmed, R.6
Kirk, A.D.7
Larsen, C.P.8
Ford, M.L.9
-
71
-
-
67650096912
-
Enhancing CD8 T-cell memory by modulating fatty acid metabolism
-
Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, Jones RG and Choi Y. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature. 2009; 460:103-107.
-
(2009)
Nature
, vol.460
, pp. 103-107
-
-
Pearce, E.L.1
Walsh, M.C.2
Cejas, P.J.3
Harms, G.M.4
Shen, H.5
Wang, L.S.6
Jones, R.G.7
Choi, Y.8
-
72
-
-
0036707521
-
PI3K-mediated negative feedback regulation of IL-12 production in DCs
-
Fukao T, Tanabe M, Terauchi Y, Ota T, Matsuda S, Asano T, Kadowaki T, Takeuchi T and Koyasu S. PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nature immunology. 2002; 3:875-881.
-
(2002)
Nature immunology
, vol.3
, pp. 875-881
-
-
Fukao, T.1
Tanabe, M.2
Terauchi, Y.3
Ota, T.4
Matsuda, S.5
Asano, T.6
Kadowaki, T.7
Takeuchi, T.8
Koyasu, S.9
-
73
-
-
62049084947
-
Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells
-
Jagannath C, Lindsey DR, Dhandayuthapani S, Xu Y, Hunter RL, Jr. and Eissa NT. Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nature medicine. 2009; 15:267-276.
-
(2009)
Nature medicine
, vol.15
, pp. 267-276
-
-
Jagannath, C.1
Lindsey, D.R.2
Dhandayuthapani, S.3
Xu, Y.4
Hunter Jr, R.L.5
Eissa, N.T.6
-
74
-
-
67650074206
-
mTOR regulates memory CD8 T-cell differentiation
-
Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen CP and Ahmed R. mTOR regulates memory CD8 T-cell differentiation. Nature. 2009; 460:108-112.
-
(2009)
Nature
, vol.460
, pp. 108-112
-
-
Araki, K.1
Turner, A.P.2
Shaffer, V.O.3
Gangappa, S.4
Keller, S.A.5
Bachmann, M.F.6
Larsen, C.P.7
Ahmed, R.8
-
75
-
-
80054094100
-
Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors
-
Thomas DL, Doty R, Tosic V, Liu J, Kranz DM, McFadden G, Macneill AL and Roy EJ. Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors. Cancer immunology, immunotherapy: CII. 2011; 60:1461-1472.
-
(2011)
Cancer immunology, immunotherapy: CII
, vol.60
, pp. 1461-1472
-
-
Thomas, D.L.1
Doty, R.2
Tosic, V.3
Liu, J.4
Kranz, D.M.5
McFadden, G.6
Macneill, A.L.7
Roy, E.J.8
-
76
-
-
75549090275
-
mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells
-
Chen C, Liu Y, Liu Y and Zheng P. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Science signaling. 2009; 2:ra75.
-
(2009)
Science signaling
, vol.2
-
-
Chen, C.1
Liu, Y.2
Liu, Y.3
Zheng, P.4
-
77
-
-
84873323853
-
The combination of IkappaB kinase beta inhibitor and everolimus modulates expression of interleukin-10 in human T-cell lymphotropic virus type-1-infected T cells
-
Nishioka C, Ikezoe T, Yang J, Udaka K and Yokoyama A. The combination of IkappaB kinase beta inhibitor and everolimus modulates expression of interleukin-10 in human T-cell lymphotropic virus type-1-infected T cells. Immunology. 2013; 138:216-227.
-
(2013)
Immunology
, vol.138
, pp. 216-227
-
-
Nishioka, C.1
Ikezoe, T.2
Yang, J.3
Udaka, K.4
Yokoyama, A.5
-
78
-
-
77958126087
-
A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation
-
Haidinger M, Poglitsch M, Geyeregger R, Kasturi S, Zeyda M, Zlabinger GJ, Pulendran B, Horl WH, Saemann MD and Weichhart T. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. Journal of immunology. 2010; 185:3919-3931.
-
(2010)
Journal of immunology
, vol.185
, pp. 3919-3931
-
-
Haidinger, M.1
Poglitsch, M.2
Geyeregger, R.3
Kasturi, S.4
Zeyda, M.5
Zlabinger, G.J.6
Pulendran, B.7
Horl, W.H.8
Saemann, M.D.9
Weichhart, T.10
-
79
-
-
50949130076
-
Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells
-
Ohtani M, Nagai S, Kondo S, Mizuno S, Nakamura K, Tanabe M, Takeuchi T, Matsuda S and Koyasu S. Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. Blood. 2008; 112:635-643.
-
(2008)
Blood
, vol.112
, pp. 635-643
-
-
Ohtani, M.1
Nagai, S.2
Kondo, S.3
Mizuno, S.4
Nakamura, K.5
Tanabe, M.6
Takeuchi, T.7
Matsuda, S.8
Koyasu, S.9
-
80
-
-
54949109311
-
The TSC-mTOR signaling pathway regulates the innate inflammatory response
-
Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, Kolbe T, Stulnig TM, Horl WH, Hengstschlager M, Muller M and Saemann MD. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity. 2008; 29:565-577.
-
(2008)
Immunity
, vol.29
, pp. 565-577
-
-
Weichhart, T.1
Costantino, G.2
Poglitsch, M.3
Rosner, M.4
Zeyda, M.5
Stuhlmeier, K.M.6
Kolbe, T.7
Stulnig, T.M.8
Horl, W.H.9
Hengstschlager, M.10
Muller, M.11
Saemann, M.D.12
-
81
-
-
0035125938
-
Sirolimus interferes with the innate response to bacterial products in human whole blood by attenuation of IL-10 production
-
Jorgensen PF, Wang JE, Almlof M, Solberg R, Okkenhaug C, Scholz T, Thiemermann C, Foster SJ and Aasen AO. Sirolimus interferes with the innate response to bacterial products in human whole blood by attenuation of IL-10 production. Scandinavian journal of immunology. 2001; 53:184-191.
-
(2001)
Scandinavian journal of immunology
, vol.53
, pp. 184-191
-
-
Jorgensen, P.F.1
Wang, J.E.2
Almlof, M.3
Solberg, R.4
Okkenhaug, C.5
Scholz, T.6
Thiemermann, C.7
Foster, S.J.8
Aasen, A.O.9
-
82
-
-
0038036797
-
Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo
-
Hackstein H, Taner T, Zahorchak AF, Morelli AE, Logar AJ, Gessner A and Thomson AW. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood. 2003; 101:4457-4463.
-
(2003)
Blood
, vol.101
, pp. 4457-4463
-
-
Hackstein, H.1
Taner, T.2
Zahorchak, A.F.3
Morelli, A.E.4
Logar, A.J.5
Gessner, A.6
Thomson, A.W.7
-
83
-
-
84877262630
-
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
-
Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L and Kroemer G. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012; 1:894-907.
-
(2012)
Oncoimmunology
, vol.1
, pp. 894-907
-
-
Vacchelli, E.1
Galluzzi, L.2
Eggermont, A.3
Fridman, W.H.4
Galon, J.5
Sautes-Fridman, C.6
Tartour, E.7
Zitvogel, L.8
Kroemer, G.9
-
84
-
-
84872801225
-
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy
-
Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L and Kroemer G. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012; 1:699-716.
-
(2012)
Oncoimmunology
, vol.1
, pp. 699-716
-
-
Galluzzi, L.1
Vacchelli, E.2
Eggermont, A.3
Fridman, W.H.4
Galon, J.5
Sautes-Fridman, C.6
Tartour, E.7
Zitvogel, L.8
Kroemer, G.9
-
85
-
-
74649085700
-
The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin
-
Rao RR, Li Q, Odunsi K and Shrikant PA. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity. 2010; 32:67-78.
-
(2010)
Immunity
, vol.32
, pp. 67-78
-
-
Rao, R.R.1
Li, Q.2
Odunsi, K.3
Shrikant, P.A.4
-
86
-
-
84886943632
-
AAV2/IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications: Evidence for IL-12 intracrine activity in DC
-
You CX, Shi M, Liu Y, Cao M, Luo R and Hermonat PL. AAV2/IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications: Evidence for IL-12 intracrine activity in DC. Oncoimmunology. 2012; 1:847-855.
-
(2012)
Oncoimmunology
, vol.1
, pp. 847-855
-
-
You, C.X.1
Shi, M.2
Liu, Y.3
Cao, M.4
Luo, R.5
Hermonat, P.L.6
-
87
-
-
84886944747
-
Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy
-
Song DG and Powell DJ. Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy. Oncoimmunology. 2012; 1:547-549.
-
(2012)
Oncoimmunology
, vol.1
, pp. 547-549
-
-
Song, D.G.1
Powell, D.J.2
-
88
-
-
84859400580
-
Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity
-
Li Q, Rao R, Vazzana J, Goedegebuure P, Odunsi K, Gillanders W and Shrikant PA. Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity. Journal of immunology. 2012; 188:3080-3087.
-
(2012)
Journal of immunology
, vol.188
, pp. 3080-3087
-
-
Li, Q.1
Rao, R.2
Vazzana, J.3
Goedegebuure, P.4
Odunsi, K.5
Gillanders, W.6
Shrikant, P.A.7
-
89
-
-
84877057592
-
Rapamycin: A rheostat for CD8(+) T-cell-mediated tumor therapy
-
Srivastava RK, Utley A and Shrikant PA. Rapamycin: A rheostat for CD8(+) T-cell-mediated tumor therapy. Oncoimmunology. 2012; 1:1189-1190.
-
(2012)
Oncoimmunology
, vol.1
, pp. 1189-1190
-
-
Srivastava, R.K.1
Utley, A.2
Shrikant, P.A.3
-
90
-
-
79953814668
-
Rapamycin increases the yield and effector function of human gammadelta T cells stimulated in vitro
-
Li H and Pauza CD. Rapamycin increases the yield and effector function of human gammadelta T cells stimulated in vitro. Cancer immunology, immunotherapy: CII. 2011; 60:361-370.
-
(2011)
Cancer immunology, immunotherapy: CII
, vol.60
, pp. 361-370
-
-
Li, H.1
Pauza, C.D.2
-
92
-
-
84886943865
-
Licensing of gammadeltaT cells for professional antigen presentation: A new role for antibodies in regulation of antitumor immune responses
-
Anderson J, Gustafsson K, Himoudi N, Yan M and Heuijerjans J. Licensing of gammadeltaT cells for professional antigen presentation: A new role for antibodies in regulation of antitumor immune responses. Oncoimmunology. 2012; 1:1652-1654.
-
(2012)
Oncoimmunology
, vol.1
, pp. 1652-1654
-
-
Anderson, J.1
Gustafsson, K.2
Himoudi, N.3
Yan, M.4
Heuijerjans, J.5
-
93
-
-
84886944354
-
Immunotherapy of acute myeloid leukemia based on gammadelta T cells
-
Gertner-Dardenne J, Fauriat C, Vey N and Olive D. Immunotherapy of acute myeloid leukemia based on gammadelta T cells. Oncoimmunology. 2012; 1:1614-1616.
-
(2012)
Oncoimmunology
, vol.1
, pp. 1614-1616
-
-
Gertner-Dardenne, J.1
Fauriat, C.2
Vey, N.3
Olive, D.4
-
94
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. The New England journal of medicine. 2007; 356:2271-2281.
-
(2007)
The New England journal of medicine
, vol.356
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, M.2
Tomczak, P.3
Dutcher, J.4
Figlin, R.5
Kapoor, A.6
Staroslawska, E.7
Sosman, J.8
McDermott, D.9
Bodrogi, I.10
Kovacevic, Z.11
Lesovoy, V.12
Schmidt-Wolf, I.G.13
-
95
-
-
84885920743
-
Interleukin-15 gene therapy and the mammalian target of rapamycin inhibitor everolimus inhibit the growth of metastatic breast cancer
-
Zhao N, Li X, He X, Qiu Y, Zhu L and Qi F. Interleukin-15 gene therapy and the mammalian target of rapamycin inhibitor everolimus inhibit the growth of metastatic breast cancer. The journal of gene medicine. 2013; 15:366-374.
-
(2013)
The journal of gene medicine
, vol.15
, pp. 366-374
-
-
Zhao, N.1
Li, X.2
He, X.3
Qiu, Y.4
Zhu, L.5
Qi, F.6
-
96
-
-
79951670258
-
Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
-
Wang Y, Wang XY, Subjeck JR, Shrikant PA and Kim HL. Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. British journal of cancer. 2011; 104:643-652.
-
(2011)
British journal of cancer
, vol.104
, pp. 643-652
-
-
Wang, Y.1
Wang, X.Y.2
Subjeck, J.R.3
Shrikant, P.A.4
Kim, H.L.5
-
97
-
-
84877940678
-
Trial watch: Peptide vaccines in cancer therapy
-
Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G and Galluzzi L. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology. 2012; 1:1557-1576.
-
(2012)
Oncoimmunology
, vol.1
, pp. 1557-1576
-
-
Vacchelli, E.1
Martins, I.2
Eggermont, A.3
Fridman, W.H.4
Galon, J.5
Sautes-Fridman, C.6
Tartour, E.7
Zitvogel, L.8
Kroemer, G.9
Galluzzi, L.10
-
98
-
-
84880688294
-
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan
-
Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, Link CJ and Prendergast GC. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology. 2012; 1:1460-1468.
-
(2012)
Oncoimmunology
, vol.1
, pp. 1460-1468
-
-
Metz, R.1
Rust, S.2
Duhadaway, J.B.3
Mautino, M.R.4
Munn, D.H.5
Vahanian, N.N.6
Link, C.J.7
Prendergast, G.C.8
-
99
-
-
77951678634
-
The role of mTOR in memory CD8 T-cell differentiation
-
Araki K, Youngblood B and Ahmed R. The role of mTOR in memory CD8 T-cell differentiation. Immunological reviews. 2010; 235:234-243.
-
(2010)
Immunological reviews
, vol.235
, pp. 234-243
-
-
Araki, K.1
Youngblood, B.2
Ahmed, R.3
-
100
-
-
84886945201
-
Advancing the field of cancer immunotherapy: MIATA consensus guidelines become available to improve data reporting and interpretation for T-cell immune monitoring
-
Hoos A, Janetzki S and Britten CM. Advancing the field of cancer immunotherapy: MIATA consensus guidelines become available to improve data reporting and interpretation for T-cell immune monitoring. Oncoimmunology. 2012; 1:1457-1459.
-
(2012)
Oncoimmunology
, vol.1
, pp. 1457-1459
-
-
Hoos, A.1
Janetzki, S.2
Britten, C.M.3
-
101
-
-
84875535374
-
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer
-
Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautes-Fridman C, Ma Y, Tartour E, Zitvogel L, Kroemer G and Galluzzi L. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology. 2012; 1:1323-1343.
-
(2012)
Oncoimmunology
, vol.1
, pp. 1323-1343
-
-
Senovilla, L.1
Vacchelli, E.2
Galon, J.3
Adjemian, S.4
Eggermont, A.5
Fridman, W.H.6
Sautes-Fridman, C.7
Ma, Y.8
Tartour, E.9
Zitvogel, L.10
Kroemer, G.11
Galluzzi, L.12
-
102
-
-
84886747363
-
Single lowdose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice
-
Malvicini M, Alaniz L, Bayo J, Garcia M, Piccioni F, Fiore E, Atorrasagasti C, Aquino JB, Matar P and Mazzolini G. Single lowdose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice. Oncoimmunology. 2012; 1:1038-1047.
-
(2012)
Oncoimmunology
, vol.1
, pp. 1038-1047
-
-
Malvicini, M.1
Alaniz, L.2
Bayo, J.3
Garcia, M.4
Piccioni, F.5
Fiore, E.6
Atorrasagasti, C.7
Aquino, J.B.8
Matar, P.9
Mazzolini, G.10
-
105
-
-
37349107870
-
The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat
-
Vogelbacher R, Wittmann S, Braun A, Daniel C and Hugo C. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation. 2007; 84:1492-1499.
-
(2007)
Transplantation
, vol.84
, pp. 1492-1499
-
-
Vogelbacher, R.1
Wittmann, S.2
Braun, A.3
Daniel, C.4
Hugo, C.5
-
106
-
-
17844385843
-
Inhibition of mammalian target of rapamycin potentiates thrombin-induced intercellular adhesion molecule-1 expression by accelerating and stabilizing NF-kappa B activation in endothelial cells
-
Minhajuddin M, Fazal F, Bijli KM, Amin MR and Rahman A. Inhibition of mammalian target of rapamycin potentiates thrombin-induced intercellular adhesion molecule-1 expression by accelerating and stabilizing NF-kappa B activation in endothelial cells. Journal of immunology. 2005; 174:5823-5829.
-
(2005)
Journal of immunology
, vol.174
, pp. 5823-5829
-
-
Minhajuddin, M.1
Fazal, F.2
Bijli, K.M.3
Amin, M.R.4
Rahman, A.5
-
107
-
-
83555164165
-
Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression
-
McKenna GJ, Trotter JF, Klintmalm E, Onaca N, Ruiz R, Jennings LW, Neri M, O'Leary JG, Davis GL, Levy MF, Goldstein RM and Klintmalm GB. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2011; 11:2379-2387.
-
(2011)
American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
, vol.11
, pp. 2379-2387
-
-
McKenna, G.J.1
Trotter, J.F.2
Klintmalm, E.3
Onaca, N.4
Ruiz, R.5
Jennings, L.W.6
Neri, M.7
O'Leary, J.G.8
Davis, G.L.9
Levy, M.F.10
Goldstein, R.M.11
Klintmalm, G.B.12
-
108
-
-
2942735384
-
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
-
Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth-Bradley J, Hanauske A and Armand JP. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004; 22:2336-2347.
-
(2004)
Journal of clinical oncology: official journal of the American Society of Clinical Oncology
, vol.22
, pp. 2336-2347
-
-
Raymond, E.1
Alexandre, J.2
Faivre, S.3
Vera, K.4
Materman, E.5
Boni, J.6
Leister, C.7
Korth-Bradley, J.8
Hanauske, A.9
Armand, J.P.10
|